A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies


Jacksonville, Fla.

Trial status:
Open for Enrollment
Why is this study being done?

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Who is eligible to participate?

Inclusion Criteria: - Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy - Have failed, refused, or have been deemed ineligible for standard therapy - Measurable disease - Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70 Exclusion Criteria: - Primary diagnosis of lymphoma or central nervous system (CNS) malignancy - History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years - Evidence of active cerebral/meningeal disease

Last updated:
IRB Number: